Search research articles
Contact Us
Filters
Showing results (21-30 of 71) with videos related to
Page
of 8
Sort By:
Chembiochem : a European Journal of Chemical Biology
|
June 24, 2010
Two-headed PROTAC: an effective new tool for targeted protein degradation
Kedra Cyrus, Marie Wehenkel, Eun-Young Choi, et al.
Therapeutic Delivery
|
October 30, 2016
Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity
Derek Reichel, Min Jae Lee, Wooin Lee, et al.
Chembiochem : a European Journal of Chemical Biology
|
October 2, 2007
Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool
Hyosung Lee, Dinesh Puppala, Eun-Young Choi, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
April 15, 2018
Next-generation proteasome inhibitors for cancer therapy
Ji Eun Park, Zachary Miller, Yearin Jun, et al.
Pharmaceutical Research
|
October 7, 2020
Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib
Preye Agbana, Min Jae Lee, Piotr Rychahou, et al.
Chemistry & Biology
|
April 28, 2007
LMP2-specific inhibitors: chemical genetic tools for proteasome biology
Yik Khuan Ho, Paola Bargagna-Mohan, Marie Wehenkel, et al.
The Biochemical Journal
|
May 23, 2012
Nitric oxide-dependent CYP2B degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2
Haiyan Sun, Choon-myung Lee, Shweta Tripathi, et al.
Chemmedchem
|
June 1, 2010
Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs
Kedra Cyrus, Marie Wehenkel, Eun-Young Choi, et al.
Molecular Pharmacology
|
October 5, 2011
Development of novel CH223191-based antagonists of the aryl hydrocarbon receptor
Eun-Young Choi, Hyosung Lee, R W Cameron Dingle, et al.
Scientific Reports
|
March 13, 2019
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
Min Jae Lee, Zachary Miller, Ji Eun Park, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 71) with videos related to
Sort By:
Page
of 8
Chembiochem : a European Journal of Chemical Biology
|
June 24, 2010
Two-headed PROTAC: an effective new tool for targeted protein degradation
Kedra Cyrus, Marie Wehenkel, Eun-Young Choi, et al.
Therapeutic Delivery
|
October 30, 2016
Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity
Derek Reichel, Min Jae Lee, Wooin Lee, et al.
Chembiochem : a European Journal of Chemical Biology
|
October 2, 2007
Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool
Hyosung Lee, Dinesh Puppala, Eun-Young Choi, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
April 15, 2018
Next-generation proteasome inhibitors for cancer therapy
Ji Eun Park, Zachary Miller, Yearin Jun, et al.
Pharmaceutical Research
|
October 7, 2020
Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib
Preye Agbana, Min Jae Lee, Piotr Rychahou, et al.
Chemistry & Biology
|
April 28, 2007
LMP2-specific inhibitors: chemical genetic tools for proteasome biology
Yik Khuan Ho, Paola Bargagna-Mohan, Marie Wehenkel, et al.
The Biochemical Journal
|
May 23, 2012
Nitric oxide-dependent CYP2B degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2
Haiyan Sun, Choon-myung Lee, Shweta Tripathi, et al.
Chemmedchem
|
June 1, 2010
Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs
Kedra Cyrus, Marie Wehenkel, Eun-Young Choi, et al.
Molecular Pharmacology
|
October 5, 2011
Development of novel CH223191-based antagonists of the aryl hydrocarbon receptor
Eun-Young Choi, Hyosung Lee, R W Cameron Dingle, et al.
Scientific Reports
|
March 13, 2019
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
Min Jae Lee, Zachary Miller, Ji Eun Park, et al.
Page
of 8